NCT01056107View on ClinicalTrials.gov

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Irritable Bowel Syndrome Constipation Predominant
Interventions
DRUG

ROSE-010

The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.

DRUG

Placebo

Placebo subcutaneous injection daily

Trial Locations (1)

55905

Mayo Clinic Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Rose Pharma A/S

UNKNOWN

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER